Literature DB >> 29453999

Evolutionary and expression analyses reveal a pattern of ancient duplications and functional specializations in the diversification of the Downstream of Kinase (DOK) genes.

Geoffrey Guittard1, Pierre Pontarotti2, Samuel Granjeaud3, Magda Rodrigues1, Laurent Abi-Rached4, Jacques A Nunès5.   

Abstract

Downstream of Kinase (DOK) proteins represent a multigenic family of adaptors that includes negative regulators of immune cell signaling. Using phylogenetics and intron/exon structure data, we show here that the seven human DOK genes (DOK1 to DOK7) form three highly divergent groups that emerged before the protostome-deuterostome split: DOK1/2/3, DOK4/5/6, and DOK7. For two of these three groups (DOK1/2/3 and DOK4/5/6), further gene duplications occurred in vertebrates and so while chordates only have three DOK genes, vertebrates have seven DOK genes over the three groups. From our expression analysis in humans, we show that each group of DOK genes has a distinct pattern of expression. The DOK1/2/3 group is immune specific, yet each of the three genes in the group has a distinct pattern of expression in immune cells. This immune specificity could thus be ancestral, with the DOK1/2/3 gene also being immune-related in protostomes. The DOK4/5/6 and DOK7 groups represent genes that are much less expressed in immune system than the DOK1/2/3 group. Interestingly, we identify a novel tyrosine based motif that is specific to the vertebrate DOK4/5/6 sequences. The evolution of the DOK genes is thus marked by a pattern of ancient duplications and functional specializations.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adapter molecules; DOK genes; Immune cell signaling

Mesh:

Substances:

Year:  2018        PMID: 29453999     DOI: 10.1016/j.dci.2018.02.011

Source DB:  PubMed          Journal:  Dev Comp Immunol        ISSN: 0145-305X            Impact factor:   3.636


  1 in total

1.  Comprehensive analysis of DOK family genes expression, immune characteristics, and drug sensitivity in human tumors.

Authors:  Yongjun Guan; Man Li; Zhendong Qiu; Junhui Xu; Yichao Zhang; Ning Hu; Xuanzhe Zhang; Wenyi Guo; Jingping Yuan; Qiao Shi; Weixing Wang
Journal:  J Adv Res       Date:  2021-06-12       Impact factor: 10.479

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.